Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Mohan M, et al. Among authors: radhakrishnan sv. Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2. Am J Hematol. 2022. PMID: 35472167 Free PMC article. No abstract available.
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Mohan M, et al. Among authors: radhakrishnan sv. Am J Hematol. 2022 Dec;97(12):E451-E453. doi: 10.1002/ajh.26728. Epub 2022 Sep 24. Am J Hematol. 2022. PMID: 36097868 Free article. No abstract available.
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Al Hadidi S, et al. Among authors: radhakrishnan sv. Bone Marrow Transplant. 2023 Apr;58(4):443-445. doi: 10.1038/s41409-022-01905-1. Epub 2022 Dec 22. Bone Marrow Transplant. 2023. PMID: 36550200 No abstract available.
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. Hammons L, et al. Among authors: radhakrishnan sv. Haematologica. 2024 Mar 1;109(3):906-914. doi: 10.3324/haematol.2023.283590. Haematologica. 2024. PMID: 37646658 Free PMC article.
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. Atanackovic D, et al. Among authors: radhakrishnan sv. Leukemia. 2020 Jan;34(1):317-321. doi: 10.1038/s41375-019-0536-3. Epub 2019 Aug 13. Leukemia. 2020. PMID: 31409922 Clinical Trial. No abstract available.
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Atanackovic D, et al. Among authors: radhakrishnan sv. Br J Haematol. 2016 Mar;172(5):685-98. doi: 10.1111/bjh.13889. Epub 2016 Jan 20. Br J Haematol. 2016. PMID: 26791002 Free article. Review.
31 results